Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorWeill Medical College of Cornell University

About this trial

The goal of this observational study is to use digital health tracking to improve how high blood pressure and other health issues are detected in pregnant refugee women. The main questions this study aims to answer are are:

* Can a digital monitoring system that checks for high blood pressure in these women be tested and refined, using clinical training and validation? * Can this digital monitoring system accurately track any related pregnancy health issues and be used to refer participants to care providers? * Can this system be used to accurately identify risks associated with the contraction of pregnancy-related conditions, such as preeclampsia and high blood pressure?

Participants will:

* Complete baseline and follow-up in-person appointments; * Complete surveys at these appointment that track their health, stress levels, and comorbidities/risks associated with pregnancy; * Be given a smartwatch fitness tracker and electronic blood pressure cuffs for at-home measurements.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Pregnant

Refugee, asylum seeking, or asylee as designated by the U.S. Government

Greater than or equal to 18 years of age

Has a personal smartphone

Disqualifiers

Unable to provide informed consent

Determined by the PI to be in an extremely vulnerable position and therefore not suited for research participation

Planned move from the New York City (NYC) area within the next 24 months

Trial population

The study population is a pregnant refugee, or asylee as designated by the U.S. Government.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Nokia-Withings BPM Connect Blood Pressure Monitor

    Device

    At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.

  • Smartwatch Devices

    Device

    Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.

Treatment groups

75 Participants
are divided into 1 treatment group
Group A: Pregnant Refugees2 interventions

Trial outcomes

Primary outcomes

1

Digital Sensitivity for detecting gestational hypertension (HTN)

The diagnostic accuracy of the digital blood pressure cuffs will be compared to the measurements taken during in-person visits.

Time frame
13 months [maximum duration of enrollment]

Secondary outcomes

1

Number of Participants that Complete All Surveys Between Appointments

The completion of weekly surveys will be assessed for each participant and the number of participants that complete all surveys sent to them will be compared to the overall number of participants enrolled.

Time frame
13 months [maximum duration of enrollment]
2

Number of Participants That Complete All Surveys at the Baseline Appointment

The number of participants that complete every single survey at the baseline appointment out of the total number of participants will be recorded.

Time frame
13 months [maximum duration of enrollment]
3

Number of Participants Referred to Physicians/Care that do not have a designated provider

Participants without designated care providers during their pregnancy will be noted and the number of participants that are successfully referred to physicians/other providers will be recorded.

Time frame
13 months [maximum duration of enrollment]
4

Number of Participants With No Comorbid Pain as Assessed by BPI-SF

Chronic pain will be evaluated using the validated Brief Pain Inventory - Short Form (BPI-SF). The mean BPI-SF score quantifies pain severity (worst, least, average, and now) and pain interference into the following: none (score 0), mild (1-4), moderate (4-6), or severe (7-10).The number of participants who score 0 on the BPI-SF will be measured.

Time frame
13 months [maximum duration of enrollment]

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Medical College of Cornell University

Lead sponsor

National Academy of Medicine

Collaborator

Cornell University

Collaborator

Apple Inc.

Collaborator